Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The GLP-1 receptor agonist exenatide is synthetic exendin-4, a peptide originally isolated from the salivary secretions of the Gila monster. Exenatide was developed as a first-in-class diabetes therapy, with immediate- and extended-release formulations. In preclinical diabetes models, exenatide enhanced glucose-dependent insulin secretion, suppressed inappropriately elevated glucagon secretion, slowed gastric emptying, reduced body weight, enhanced satiety, and preserved pancreatic β-cell function. In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (T2DM) and were associated with weight loss. AREAS COVERED: This article reviews the development of exenatide from its discovery and preclinical investigations, to the elucidation of its pharmacological mechanisms of action in mammalian systems. The article also presents the pharmacokinetic profiling and toxicology studies of exenatide, as well as its validation in clinical trials. EXPERT OPINION: GLP-1 receptor agonists represent a new paradigm for the treatment of patients with T2DM. By leveraging incretin physiology, a natural regulatory system that coordinates oral nutrient intake with mechanisms of metabolic control, these agents address multiple core defects in the pathophysiology of T2DM. Studies have identified unique benefits including improvements in glycemic control and weight, and the potential for beneficial effects on the cardiometabolic system without the increased risk of hypoglycemia associated with insulin therapy. Peptide hormone therapeutics can offer significant advantages over small molecule drug targets when it comes to specificity, potency, and more predictable side effects. As exemplified by exenatide, injectable peptides can be important drugs for the treatment of chronic diseases, such as T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 3×
“The incretin GLP-1 was the focus of much investigation at this time due to its favorable spectrum of antidiabetic actions, which include the amplification of glucose-stimulated insulin secretion [6], the slowing of gastric emptying [7], the inhibition of inappropriately elevated glucagon secretion [8], and a purported…”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“2 GLP-1 and the GLP-1 receptor GLP-1 is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion directly into the hepatic portal circulation where a glucose sensor is located [11,13-19].”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 2×
“In hepatocytes, GLP-1 stimulated glycogen synthase a and this effect was blocked by the GLP-1 receptor antagonist exendin [9-39]amide.”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 receptor was subsequently characterized as a seven-transmembrane domain, G-protein--coupled receptor with confirmed expression in pancreatic periductal and b-cells, kidney, heart, blood vessels, stomach, and brain [27-32].”
BackgroundResultEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 5×
“Seminal studies by Eng and coworkers showed that exendin-4 binds to acinar cells at sites named at the time “exendin receptors” [42]”.”
BackgroundInfluentialPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“3 Adverse event surveillance issues The incidence of acute pancreatitis is rare in patients with T2DM (although elevated compared with the general population) whether or not they are being treated with exenatide or other diabetes drugs [103,104,109-111,125-127].”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 2×
“1 The incretin effect The “incretin effect” describes the observation that administration of oral glucose stimulates insulin secretion to a greater extent than does intravenously administered glucose [10,11].”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 3×
“GLP receptor knockout mice exhibit elevated blood glucose concentrations following an oral glucose challenge, coupled with lower-than-normal plasma insulin concentrations [34,36,37].”
BackgroundKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 1×
“demonstrated sustained improvement in glycemic control and increased plasma insulin levels with concomitant administration of exenatide to streptozotocin-treated mice [71].”
BackgroundLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“In rodent models, GLP-1 and exendin-4 were neuroprotective against insults that modeled stroke and Parkinson’s disease, an effect antagonized by a GLP-1 receptor antagonist and absent in cells from GLP-1 receptor KO mice [88].”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“In wild-type or apolipoprotein E-deficient mice, chronic exenatide administration inhibited monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve, possibly by inhibiting the inflammatory response in macrophages [82].”
BackgroundBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 8×
“In blinded, placebo-controlled and openlabel, comparator-controlled, Phase 3 clinical trials, exenatide BID significantly reduced glycosylated hemoglobin (HbA1c, a measure of average blood glucose concentrations over the previous 3 months) with a mean effect of --1.0% in patients with T2DM who were unable to achieve a…”
BackgroundInfluentialGlucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 2×
“In nonclinical models, pharmacological dosing with GLP-1 is associated with pancreatic islet neogenesis, b-cell proliferation, and increased b-cell mass [20-23].”
BackgroundEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · cited 2×
“2 GLP-1 and the GLP-1 receptor GLP-1 is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion directly into the hepatic portal circulation where a glucose sensor is located [11,13-19].”
BackgroundYoung, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · cited 1×
“reported that activation of central GLP-1 receptors in anorexic rats suppressed food reward/motivation by interacting with the mesolimbic system, suggesting a novel mechanism by which the GLP-1R stimulation may affect feeding-oriented behavior [73].”
BackgroundMeloni, A. R., DeYoung, M. B., Lowe, C., & Parkes, D. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01663.x · Cited by 407
Self-citationFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 2×
“2 GLP-1 and the GLP-1 receptor GLP-1 is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion directly into the hepatic portal circulation where a glucose sensor is located [11,13-19].”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“Further, both GLP-1 and exendin-4 were able to protect cultured rat hippocampal neurons from glutamate-induced excitotoxic cell apoptosis in a concentration- and cAMP-dependent manner [86].”
BackgroundBiochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · cited 1×
“In one earlier preclinical report, signs of inflammation were observed in normal rats treated subchronically with exenatide at approximately 10 times the clinical dose [95].”
BackgroundSimonsen, L., Holst, J. J., & Deacon, C. F. (2006) · Diabetologia · doi:10.1007/s00125-005-0128-9 · Cited by 133
Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125
Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
Vrang, N., Jelsing, J., Simonsen, L., Jensen, A. E., Thorup, I., Søeborg, H., & Knudsen, L. B. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2012 · Cited by 92 · cited 1×
“Furthermore, similar findings were recently reported (lack of adverse effects on the exocrine pancreas) in ZDF rats treated with exenatide or the GLP-1 analogue liraglutide [98].”
BackgroundEx vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)
Hiles, R. A., Bawdon, R. E., & Petrella, E. M. (2003) · Human & Experimental Toxicology · doi:10.1191/0960327103ht402oa · Cited by 46 · cited 1×
“025) [93].”
Research works printed but not linked: 97
- 10.1161/ATVBAHA.107.147538 · DOI · Paper page
- 10.1159/000194739 · DOI
- 10.2337/diacare.19.6.580 · DOI · Paper page
- 10.1016/j.mce.2008.08.012 · DOI · Paper page
- 10.1007/s001250050613 · DOI · Paper page
- Nauck MA, 1997, Am J Physiol, 273, E981
- 10.1055/s-2004-826161 · DOI
- 10.3109/9780203217412-17 · DOI
- Edvell A, 1999, Endocrin, 140, 778, 10.1210/endo.140.2.6514 · doi:10.1210/endo.140.2.6514 · Paper page
- 10.2337/diabetes.49.5.741 · DOI · Paper page
- 10.1146/annurev.med.57.110104.115624 · DOI · Paper page
- 10.1172/JCI119482 · DOI · Paper page
- 10.2337/diab.44.9.1126 · DOI · Paper page
- 10.1210/en.136.8.3585 · DOI · Paper page
- Raufman JP, 1992, J Biol Chem, 267, 21432, 10.1016/S0021-9258(19)36628-1 · DOI · Paper page
- 10.3109/10606820213687 · doi:10.3109/10606820213687 · Paper page
- 10.1016/j.regpep.2003.10.028 · DOI · Paper page
- 10.1210/endo.137.7.8770921 · DOI · Paper page
- Meloni AR, 2012, Diab Obes Metab
- 10.2337/diabetes.47.4.646 · DOI · Paper page
- 10.2337/diabetes.47.7.1046 · DOI · Paper page
- 10.2337/diabetes.47.4.632 · DOI · Paper page
- 10.2337/diabetes.48.10.1979 · DOI · Paper page
- 10.2337/diabetes.50.8.1720 · DOI · Paper page
- 10.2337/diabetes.52.2.365 · DOI · Paper page
- 10.3949/ccjm.76.s5.03 · DOI · Paper page
- 10.1074/jbc.272.7.4108 · DOI · Paper page
- 10.2337/diab.42.11.1678 · DOI · Paper page
- 10.1016/0167-0115(96)00135-8 · DOI
- 10.1016/0196-9781(94)90204-6 · DOI
- 10.1016/0922-4106(94)90085-X · DOI
- 10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L · DOI · Paper page
- 10.1016/S0165-1838(99)00086-7 · DOI
- Yang H, 1998, Am J Physiol, 273, C675, 10.1152/ajpcell.1998.275.3.C675 · DOI · Paper page
- 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
- 10.1053/meta.2001.22519 · DOI · Paper page
- 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 10.1007/s001250051111 · DOI · Paper page
- Gedulin B, 1999, Diabetes, 48, A199
- 10.2337/diacare.24.2.371 · DOI · Paper page
- 10.1038/sj.ijo.0803284 · DOI
- 10.2337/diabetes.50.7.1562 · DOI · Paper page
- 10.2337/diabetes.51.5.1443 · DOI · Paper page
- 10.1210/en.2004-1349 · DOI · Paper page
- 10.1002/ddr.1195 · DOI · Paper page
- Eng J, 1996, Diabetes, 45, 152A
- 10.1530/eje.0.1500097 · DOI · Paper page
- Parkes D, 2001, Diabetes, 50, A313
- 10.2337/diabetes.52.3.734 · DOI · Paper page
- 10.1152/ajpendo.00030.2002 · DOI · Paper page
- 10.1007/s00125-002-0828-3 · DOI · Paper page
- Jodka C, 1998, Diabetes, 47, A403
- Kinzig KP, 2002, J Neurosci, 22, 10470, 10.1523/JNEUROSCI.22-23-10470.2002 · DOI · Paper page
- Egan JM, 1994, Endocrinology, 135, 2070, 10.1210/endo.135.5.7956929 · doi:10.1210/endo.135.5.7956929 · Paper page
- 10.1677/jme.0.0190241 · DOI · Paper page
- 10.1089/met.2008.0095 · DOI · Paper page
- 10.1016/j.bbrc.2009.01.003 · DOI · Paper page
- 10.1186/1475-2840-9-32 · DOI · Paper page
- 10.1016/j.jacc.2008.10.033 · DOI · Paper page
- 10.1186/1475-2840-9-76 · DOI · Paper page
- 10.1007/s00125-009-1611-5 · DOI · Paper page
- 10.1124/jpet.300.3.958 · DOI · Paper page
- 10.1016/j.expneurol.2006.09.028 · DOI · Paper page
- 10.1371/journal.pone.0032008 · DOI · Paper page
- 10.2174/138920006776873490 · DOI · Paper page
- 10.1124/dmd.111.042291 · DOI
- 10.1152/ajpendo.00479.2010 · DOI · Paper page
- 10.2337/db09-0626 · DOI · Paper page
- Tatarkiewicz K, 2011, Diabetologia, 54, 185
- Bhavsar S, 2012, Curr Diab Rev
- 10.1016/j.clinthera.2012.04.013 · DOI · Paper page
- MacConell L, 2012, Diabetes Metab Syndr Obes, 5, 29
- MacConell L, 2012, Diabetes, 61, A598
- 10.3810/pgm.2010.05.2149 · DOI · Paper page
- 10.1089/dia.2011.0050 · DOI · Paper page
- 10.2337/dc10-0482 · DOI · Paper page
- 10.1111/j.1464-5491.2012.03652.x · DOI · Paper page
- 10.1111/j.1365-2125.2007.02890.x · DOI · Paper page
- 10.1038/ajh.2009.245 · DOI · Paper page
- 10.1093/eurheartj/ehr309 · DOI · Paper page
- 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
- 10.1210/jc.2011-3456 · DOI · Paper page
- 10.1007/s00125-011-2440-x · DOI
- 10.1210/jc.2003-032001 · DOI · Paper page
- 10.1530/EJE-11-0330 · DOI · Paper page
- 10.2337/dc11-0096 · DOI · Paper page
- Buse JB, 2012, Lancet
- 10.1111/j.1463-1326.2011.01533.x · DOI
- 10.1345/aph.1M676 · DOI · Paper page
- 10.1185/03007990902820519 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01376.x · DOI · Paper page
- Raufman JP, 1982, Am J Physiol, 242, G470
- 10.1046/j.1471-4159.1996.67051982.x · DOI · Paper page
- 10.1053/meta.2000.6251 · DOI
- 10.1055/s-2002-29087 · DOI · Paper page
- 10.1007/s00125-005-1795-2 · DOI
- 10.1016/j.ijpharm.2008.01.015 · DOI
Cited by
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Self-citation
Metadata
- Authors
- Parkes, D. G., Mace, K. F., & Trautmann, M. E.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2012-12-12
- Volume
- 8
- Issue
- 2
- Pages
- 219-244
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2059228484
- Cited by
- 108
- References
- 35
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.